Sign in
Taking people in NetherlandsPhase 2

Targeted Drug Before Surgery for BRAF-Mutated Anaplastic Thyroid Cancer

Tests BRAF and MEK inhibitor drugs before surgery in adults with anaplastic thyroid cancer.

Key facts

Who runs it
Leids Universitair Medisch Centrum (LUMC)
Where
Leiden, NetherlandsSee the site
Registry title
NEOAC
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
21 Jan 2025
Expected to end
1 Nov 2027
Type of study
Interventional
Record updated
17 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with anaplastic thyroid cancer that carries a BRAF V600E/K mutation, has not spread to distant organs, and has had no earlier cancer treatment.

Age
Over 18 years old
Sex
All sexes
Disease stage
Anaplastic thyroid cancer confirmed by tissue tests (centrally reviewed). No distant metastases (M0). Airway free or secured.
Earlier treatment
No earlier systemic cancer treatment (including chemotherapy, immunotherapy, oncolytic viral therapy). No earlier radiotherapy to the site of interest.
Biomarker or test result
BRAFV600E/K mutation confirmed in the primary tumor tissue.

Main reasons for not taking part

  • Another cancer within 2 years before the ATC diagnosis (except basal cell skin cancer and in situ carcinoma)
  • Poorly differentiated transformation of an earlier differentiated thyroid cancer
  • Distant metastases
  • Pregnancy or nursing
  • Medical conditions that the investigator thinks would make treatment hazardous

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Informed consent
  • No prior anticancer systemic treatment (including chemotherapy, immunotherapy, oncolytic viral therapy, other systemic therapies)
  • No prior radiotherapy to site of interest
  • Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥ 1.0x109/L, Platelets ≥ 100 x109/L, Hemoglobin ≥ 6.5 mmol/L, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, Total bilirubin ≤ 1.5 X ULN, INR and PTT in normal range, LDH < 2xULN. Serum creatinine ≤ 1.5 × ULN; or calculated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula; or estimated glomerular filtration rate > 50 mL/min/1.73m2
  • Absence of additional severe and/or uncontrolled concurrent disease
  • Age over 18 years old
  • World Health Organization (WHO) Performance Status 0 or I
  • Histologically confirmed ATC (centrally reviewed)
  • Confirmed presence of BRAFV600E/K mutation in primary tumor tissue
  • No distant metastases (M0)
  • Free or secured airway
  • Able to swallow pills
  • Patients must have undergone complete disease staging including: PET-CT scan and CT-neck/thorax/abdomen

Who cannot take part

  • Poorly differentiated transformation of previous differentiated thyroid cancer
  • History of cancer within 2 years from diagnosis of ATC (exception: basal cell skin cancer, in situ carcinoma)
  • Underlying medical conditions that, in the Investigator's opinion, will make the administration of study treatment hazardous or obscure the interpretation of toxicity determination or adverse events
  • History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes, significant arrhythmias and severe valvular disease must be evaluated for risks of undergoing general anesthesia
  • No informed consent
  • Presence of distant metastases
  • Pregnancy or nursing

Where in Netherlands

  • LUMCLeiden, NetherlandsTaking people

About the trial

What the trial wants to find out

This study aims to increase the number of patients that undergo a successful R0 tumor resection after neo-adjuvant BRAF/MEK inhibitor treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
(NEOAC) NEO- and Adjuvant Targeted therapy in braf-mutated Anaplastic Cancer of the Thyroid - a prospective, non-randomized, single center, open-label phase II study.
Plain-language title
Targeted Drug Before Surgery for BRAF-Mutated Anaplastic Thyroid CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
17 February 2025